book
histori
interferon
ifn
toin
pieter
affirm
ifn
consid
one
modern
medicin
famou
infam
drug
histori
repres
exampl
therapeut
surviv
face
sever
cycl
promis
disappoint
miracl
drug
therapeut
use
ifn
enhanc
understand
drug
manufactur
market
play
role
push
boundari
research
post
penicillin
era
genet
revolut
medicin
worth
note
despit
enorm
effort
produc
natur
recombin
type
ifn
huge
amount
research
perform
biolog
mechan
ifn
action
remain
part
elus
exploit
clinic
still
base
knowledg
biolog
earlier
era
question
also
aris
whether
still
room
appropri
use
type
ifn
infecti
diseas
cancer
whether
volum
new
inform
mechan
action
properli
incorpor
clinic
applic
specif
address
issu
use
briefli
retrac
histori
type
ifn
anticanc
antivir
drug
hype
potenti
antivir
drug
studi
ifn
begin
attract
wide
attent
effort
molecularli
defin
purifi
ifn
protein
remain
fruitless
year
mani
scientist
openli
skeptic
properti
ascrib
ifn
includ
exist
nevertheless
method
product
ifn
develop
cultur
human
leukocyt
gresser
laboratori
addit
natur
ifn
produc
partial
purifi
finland
red
cross
cantel
use
first
clinic
trial
osteosarcoma
patient
follow
observ
type
ifn
antitumor
effect
obtain
experiment
model
gresser
et
al
mani
attempt
made
demonstr
activ
natur
ifn
cancer
type
potenti
associ
viral
origin
juvenil
laryng
papillomatosi
human
condylomata
acuminata
hodgkin
diseas
acut
leukemia
children
multipl
myeloma
other
earli
result
consid
encourag
treatment
schedul
requir
optim
combin
scheme
requir
formul
optim
effect
regard
true
viral
infect
recognit
hepat
b
viru
hbv
may
caus
chronic
infect
lead
cirrhosi
hepatocellular
carcinoma
suggest
virusinfect
patient
could
efficaci
treat
ifn
ifn
enthusiast
rememb
famou
sentenc
pleasant
clinic
exploit
type
interferon
ifn
antivir
antineoplast
agent
base
properti
origin
attribut
cytokin
famili
schedul
reflect
antivir
antiprolif
activ
nevertheless
type
ifn
emerg
central
activ
innat
immun
current
schedul
treatment
chronic
hepat
c
hematolog
solid
tumor
base
continu
administr
recombin
type
ifn
pegyl
formul
disregard
viral
resist
host
genet
variant
predict
treatment
outcom
mechan
refractori
new
administr
schedul
combin
type
ifn
new
drug
increas
monitor
patient
suscept
type
ifn
expect
provid
new
life
valuabl
cytokin
elsevi
ltd
right
reserv
surpris
learn
interferon
may
effect
establish
chronic
infect
caus
poorli
understood
extrem
import
dna
viru
written
new
england
journal
medicin
ho
discoveri
made
greenberg
colleagu
abil
ifn
depress
daneparticleassoci
dna
dna
polymeras
core
antigen
chronic
activ
hepat
base
preliminari
posit
result
ifnbas
antivir
antitumor
therapi
quickli
becam
hope
among
potenti
medic
armamentarium
tumor
viral
infect
fig
howev
success
clone
type
ifn
cdna
first
cytokin
ever
clone
identif
ifn
gene
famili
ifn
research
join
mainstream
scientif
enterpris
specif
shigekazu
nagata
sidney
pestka
independ
identifi
express
ifn
alpha
escherichia
coli
protein
rapidli
purifi
monoclon
antibodi
use
research
clinic
trial
thank
express
recombin
protein
yeast
pharmaceut
compani
produc
two
type
recombin
ifn
substanti
amount
clinic
use
oncolog
infecti
diseas
ifn
alpha
ifn
alpha
subsequ
approv
therapeut
treatment
hairi
cell
leukemia
fig
ifn
beta
also
clone
produc
suffici
quantiti
clinic
use
ifn
standard
care
certain
diseas
decad
opinion
author
period
adequ
effort
made
address
actual
mechan
ifn
action
character
factor
could
influenc
ifn
treatment
outcom
henc
aim
discuss
issu
belief
care
address
fulli
appreci
efficaci
ifn
therapeut
agent
type
ifn
famili
human
consist
ifn
alpha
subtyp
plu
ifn
beta
ifn
epsilon
ifn
kappa
ifn
omega
avail
ifn
prepar
use
clinic
practic
belong
type
ifn
famili
tabl
type
ifn
subtyp
elicit
antivir
antiprolif
immunomodulatori
respons
bind
share
cell
surfac
receptor
interestingli
ifn
alpha
subtyp
differ
gene
induct
profil
variabl
antiprolif
antivir
immunolog
properti
howev
subtyp
type
ifn
name
ifn
alpha
use
therapeut
practic
remain
ifn
subtyp
repres
untap
reservoir
opportun
follow
section
summar
common
applic
ifn
alpha
oncolog
virolog
first
attempt
use
ifn
osteosarcoma
mani
tumor
test
sensit
ifn
treatment
among
number
sensit
tumor
identifi
see
tabl
first
respons
malign
hairi
cell
leukemia
hcl
ifn
induc
reduct
cytopenia
elimin
hairi
cell
blood
well
reduct
bone
marrow
fibrosi
although
ifn
longer
consid
firstlin
therapi
hcl
still
recommend
cytopen
patient
increas
granulocyt
level
order
mount
stronger
antiinfect
respons
antibiot
antifung
therapi
sinc
ifn
use
primarili
hematolog
malign
chronic
myelogen
leukemia
multipl
myeloma
nonhodgkin
lymphoma
kaposi
sarcoma
aid
patient
mycosi
fungoid
malign
despit
clear
vitro
effect
malign
cell
prolifer
despit
numer
clinic
trial
exact
role
manag
diseas
remain
uncertain
continu
administr
million
iu
everi
day
alon
combin
melanoma
surgeri
chemotherapeut
drug
consid
best
treatment
avail
induct
well
mainten
phase
treatment
multipl
myeloma
exampl
among
patient
object
respons
induct
chemotherapi
treat
ifn
significantli
longer
durat
surviv
contrast
indol
nonhodgkin
lymphoma
follicular
lymphoma
ifn
treatment
associ
overal
surviv
benefit
although
might
prolong
progressionfre
surviv
current
use
ifn
compet
new
drug
thalidomid
lenalidomid
bortezomib
success
use
myeloma
treatment
imatinib
tyrosin
kinas
inhibitor
mainstay
treatment
chronic
myelogen
leukemia
ifn
rare
use
malign
despit
evid
addit
ifn
current
protocol
ceopbleo
chop
cvp
chvp
mopp
mainten
therapi
follicular
lymphoma
improv
progressionfre
surviv
net
benefit
overal
surviv
less
evid
ifn
associ
signific
toxic
may
major
impact
patient
qualiti
life
mantl
cell
lymphoma
rituximab
combin
chop
bendamustin
care
evalu
clinic
trial
bortezomib
nfkb
inhibitor
lenalidomid
approv
agent
similarli
kaposi
sarcoma
mycosi
fungoid
patient
differ
treatment
option
addit
ifn
rel
low
number
case
actual
reduc
qualiti
analys
necessari
properli
defin
superior
treatment
regimen
rel
treatment
renal
cell
carcinoma
rcc
melanoma
two
solid
tumor
demonstr
success
ifn
therapi
although
armamentarium
system
therapi
two
tumor
undergon
dramat
chang
recent
year
particular
cytokinebas
therapi
includ
ifn
rcc
replac
vascularendotheli
growth
factor
vegf
mammalian
target
rapamycin
mtor
inhibitor
low
intermedi
risk
diseas
pazopanib
sunitinib
combin
bevacizumab
plu
ifn
consid
wherea
combin
target
agent
eg
sunitinib
combin
ifn
gener
plagu
high
grade
toxic
therapi
malign
melanoma
object
intens
research
assess
efficaci
immunotherapeut
strategi
treatment
yet
shown
superior
efficaci
ifn
adjuv
phase
efficaci
ifn
treatment
set
low
high
dose
still
debat
number
trial
ongo
assess
whether
ifn
associ
differ
vaccin
strategi
reduc
risk
recurr
resect
metastat
melanoma
patient
conclus
despit
multipl
effect
ifn
varieti
malign
rang
antiangiogen
potent
immunomodulatori
differentiationinduc
antiprolif
proapoptot
ifn
still
administ
follow
schedul
use
first
clinic
trial
use
supersed
new
effect
less
toxic
drug
current
sever
approv
ifn
formul
use
treat
chronic
viral
infect
see
tabl
main
indic
addit
hepat
b
viru
hbv
hcv
infect
chronic
viral
infect
herp
zoster
herp
simplex
cytomegaloviru
hiv
papillomaviru
infect
effect
treat
ifn
alpha
ifn
beta
parallel
prophylaxi
treatment
acut
respiratori
viral
infect
rhinoviru
influenza
viru
coronaviru
evalu
introduct
effect
antivir
compound
acyclovir
analog
herpesvirus
azidothymidin
proteas
inhibitor
hiv
greater
therapeut
effect
reduc
side
effect
rapidli
reduc
commerci
interest
ifn
antivir
evalu
ifn
treatment
viral
infect
imposs
task
thu
discuss
focus
type
ifn
treatment
hcv
infect
inde
use
ifn
antihcv
agent
excel
exampl
mix
partial
success
pend
challeng
reflect
difficulti
encount
therapeut
use
power
biolog
weapon
initi
choic
ifn
alpha
potenti
treatment
chronic
hepat
c
chc
hoofnagl
rather
empir
sinc
natur
ifn
recombin
ifn
alpha
formul
drug
avail
treatment
patient
suffer
chc
associ
limit
rate
sustain
virolog
respons
svr
rang
addit
ribavirin
rbv
recombin
ifn
alpha
increas
svr
rate
pegifn
alpha
formul
specif
pegifn
alpha
pegifn
alpha
inert
polyethylen
glycol
attach
convent
ifn
molecul
introduc
clinic
practic
basi
longer
halflif
fig
improv
pharmacokinet
properti
standard
ifn
alpha
prepar
led
svr
patient
infect
hcv
genotyp
gt
therefor
surpris
entri
market
pegyl
form
ifn
alpha
pegifn
number
compani
develop
modifi
ifn
novel
ifn
deliveri
system
hope
achiev
improv
pharmacokinet
pharmacodynam
properti
potent
immunomodulatori
effect
better
toler
list
new
ifn
alpha
prepar
current
avail
provid
tabl
recent
avail
sever
directli
act
antivir
agent
daa
hcv
mainli
inhibitor
viral
protein
offer
possibl
ifnfre
antihcv
treatment
although
move
daa
therapi
greatli
increas
svr
rate
offer
new
treatment
inelig
nonrespond
hcv
posit
patient
actual
price
daa
exceedingli
high
new
drug
associ
develop
drug
resist
thu
call
question
choic
abandon
old
consolid
therapeut
road
time
new
antivir
agent
boost
host
innat
immun
target
specif
cellular
pathway
hosttarget
antivir
hta
also
emerg
altern
antivir
therapi
among
tolllik
receptor
tlr
retino
acidinduc
gene
rigi
eg
ppprna
agonist
miravirsen
strategi
link
ifn
system
emphas
critic
role
ifn
orchestr
innat
immun
respons
necess
unravel
pleiotrop
biolog
action
ifn
type
ifn
prepar
remain
valid
therapeut
option
due
broadspectrum
antivir
properti
readi
avail
treatment
emerg
zoonot
viral
diseas
includ
time
vaccin
avail
preclud
vaccin
onset
outbreak
intens
clinic
research
therapeut
use
type
ifn
parallel
similar
effort
defin
determin
confer
cell
sensit
refractori
specif
effort
character
factor
affect
ifn
therapi
outcom
compar
oncolog
virolog
larg
part
viral
therapi
suit
complex
relationship
host
viru
ifn
respons
likewis
knowledg
acquir
virolog
field
fulli
exploit
explain
failur
ifn
treatment
cancer
patient
ifn
activ
mediat
bind
receptor
activ
jakstat
signal
pathway
result
induct
express
hundr
ifnstimul
gene
isg
review
type
ifn
signal
common
heterodimer
receptor
compos
low
highaffin
subunit
yet
noncomplet
elucid
mechan
drive
differ
biolog
signal
administ
high
dose
ifn
devoid
toxic
effect
indic
action
must
finetun
oppos
enhanc
suppress
signal
upon
ligand
engag
signal
complex
rapidli
intern
endocytosi
subsequ
ubiquitin
degrad
marijanov
et
al
show
surfac
halflif
h
unstimul
cell
half
life
reduc
h
cell
stimul
ifn
alpha
nonrespons
state
ifntreat
cell
shown
last
day
wherea
ifn
remov
express
cell
surfac
return
nearli
control
level
within
h
consequ
observ
continu
administr
high
dose
ifn
pegyl
formul
determin
unwant
decreas
receptor
express
cell
surfac
repres
one
earliest
activ
mechan
refractori
ifn
given
effect
type
ifn
infect
malign
immun
cell
mediat
receptor
modul
ifnar
level
may
expect
play
domin
role
shape
extent
durat
type
ifn
respons
altogeth
observ
argu
ration
design
ifnbas
therapi
care
consid
aspect
ifn
receptor
biolog
indic
new
strategi
stabil
inhibit
degrad
need
similarli
evalu
basal
express
ifnar
complex
downregul
follow
treatment
compon
standard
care
ifntreat
patient
mice
repeatedli
inject
murin
ifn
alpha
shown
becom
refractori
stimul
within
hour
first
inject
suppressor
cytokin
signal
soc
protein
particular
shown
import
neg
regul
type
type
ii
ifn
signal
inhibit
bind
ifnar
suppress
jak
activ
respect
similarli
ubiquitin
carboxytermin
hydrolas
ubiquitin
proteas
shown
requir
induct
longlast
desensit
state
bind
vivo
displac
led
inhibit
downstream
phosphoryl
cascad
signal
event
note
administr
pegifn
alpha
patient
chc
shown
activ
jakstat
pathway
first
day
follow
inject
rapidli
induc
express
despit
fact
serum
concentr
pegifn
alpha
remain
high
entir
week
observ
argu
superior
antivir
efficaci
pegifn
alpha
relat
constitut
activ
ifn
signal
pathway
rather
induct
immun
responseassoci
gene
pegifn
mechan
underli
increas
efficaci
sinc
defici
either
amplifi
ifn
antivir
proinflammatori
action
activ
may
repres
promis
therapeut
target
improv
benefit
ifn
treatment
cancer
well
viral
diseas
regard
identifi
poor
prognost
marker
ifn
alpha
therapi
patient
chronic
hepat
c
vitro
silenc
human
cell
potenti
antivir
activ
ifn
similarli
level
increas
sever
human
tumor
includ
nonsmal
cell
lung
cancer
silenc
mous
lung
cancer
cell
render
cell
less
tumorigen
sensibl
growthinhibitori
proapoptot
effect
ifn
vitro
sever
recent
paper
suggest
major
role
differ
microrna
mir
regul
ifn
respons
regard
broadli
suppress
express
ifnarjakstat
pathway
compon
cell
suppress
function
thu
act
enhanc
jakstat
signal
importantli
patient
hepatocellular
carcinoma
reduc
express
tumor
display
signific
improv
overal
surviv
receiv
adjuv
therapi
ifn
alpha
indic
express
statu
inde
help
stratifi
patient
respect
respons
ifn
therapi
sinc
begin
ifn
therapi
chc
evid
hcv
infect
subject
respond
differ
ifn
administr
variabl
respons
total
unexpect
basi
result
obtain
vitro
experiment
variabl
stimul
intens
effort
aim
understand
underli
mechan
resist
ifn
treatment
well
character
predict
biomark
could
use
identifi
patient
like
respond
ifn
treatment
import
emphas
although
mani
determin
ifn
respons
identifi
much
work
still
requir
fulli
appreci
potenti
type
ifn
action
two
variabl
modul
ifn
respons
viral
host
determin
discuss
separ
highli
variabl
respons
rate
observ
hcv
patient
treat
ifn
alpha
depend
wellestablish
viral
factor
viral
load
patient
high
pretreat
viral
load
poor
longterm
outcom
compar
patient
low
viral
load
increas
risk
treatment
failur
observ
predomin
hcv
gt
subtyp
hcv
decay
kinet
also
import
factor
estim
effect
antivir
therapi
fulli
appreci
variabl
ifn
respons
hcv
patient
also
import
consid
polymorph
hcv
genom
instanc
enomoto
et
al
found
hcv
viru
four
amino
acid
substitut
region
term
ifnsensitivitydetermin
region
isdr
prior
therapi
strongli
correl
svr
ifn
alpha
therapi
japanes
patient
number
amino
acid
substitut
thought
independ
predictor
ifn
treatment
success
initi
find
confirm
studi
japanes
patient
howev
sever
report
europ
unit
state
fail
show
correl
isdr
mutat
ifn
respons
later
establish
isdr
necessari
suffici
interact
ifn
induc
pkr
enzym
addit
amino
acid
call
pkr
bind
domain
pkrbd
distal
isdr
also
requir
latter
region
shown
hinder
pkr
dimer
result
repress
pkr
function
translat
factor
inde
mutat
within
pkrbd
hcv
associ
longterm
sustain
respons
ifn
alpha
pegifn
alpharbv
therapi
region
hcv
especi
phosphoryl
homolog
domain
pephd
region
ctermin
portion
shown
contain
specif
sequenc
differ
hcv
genotyp
differenti
affect
ifn
respons
interestingli
hcv
protein
subvert
type
ifn
respons
vitro
whether
hcv
evas
strategi
activ
vivo
influenc
ifn
treatment
respons
unclear
consider
togeth
indic
close
associ
hcv
genet
variabl
antivir
treatment
outcom
lead
import
gener
question
infect
specif
hcv
gt
andor
mutat
specif
region
genom
abl
affect
endogen
productionact
ifn
express
isg
high
variabl
simpli
reflect
authent
adapt
hcv
immun
respons
includ
type
ifn
express
function
attempt
answer
question
made
issu
remain
larg
unresolv
sinc
initi
use
ifn
chc
therapi
understood
differ
pretreat
host
factor
age
sex
bodi
weight
insulin
resist
liver
fibrosi
significantli
affect
virolog
respons
ifn
pegifn
alpharibavirin
therapi
variabl
ifn
respons
howev
could
entir
explain
abovement
factor
recent
two
singl
nucleotid
polymorph
snp
tc
tg
region
interleukin
il
lambda
chromosom
definit
associ
spontan
ifn
treatmentinduc
viral
clearanc
hcv
infect
togeth
discoveri
snp
becam
clear
concert
action
multipl
isg
must
also
consid
fulli
understand
limit
ifn
alpha
treatment
administr
ifn
induc
upregul
isg
pbmc
liver
hcvinfect
individu
type
especi
magnitud
ifn
induc
respons
differ
respond
nonrespond
hcv
posit
individu
hcv
infect
patient
less
like
respond
ifn
alpha
therapi
exhibit
paradox
higher
constitut
isg
express
compar
achiev
good
respons
notabl
presenc
high
basal
level
isg
associ
lack
increas
express
ifn
administr
molecular
mechan
link
baselin
isg
induct
ifn
nonrespons
remain
current
unknown
propos
refractori
exogen
ifn
could
reflect
presenc
high
pretreat
level
neg
regul
andor
reflect
ifn
transduct
pathway
satur
upregul
isg
liverderiv
biopsi
chronic
hcv
infect
patient
larg
sustain
hepatocyt
although
kupffer
cell
local
sourc
ifn
promot
basal
express
isg
hepatocyt
nonrespond
addit
signific
correl
serum
intrahepat
viral
load
isg
express
level
suggest
respons
ineffect
term
hcv
replic
control
also
clear
whether
type
iii
ifn
driver
basal
isg
induct
regard
type
iii
ifn
differ
kinet
product
level
isg
induct
clearli
detect
hierarchi
pathway
sever
impair
liverderiv
tissu
chronic
hcv
infect
patient
lack
specif
signatur
type
iii
ifn
liver
hcv
posit
subject
character
presenc
high
endogen
level
isg
could
indic
sever
impair
earli
host
defens
pathway
addit
specul
pretreat
isg
respons
may
reflect
type
iii
ifn
produc
respons
hcv
replic
well
ifnindepend
mechan
trigger
hcv
altern
pathway
instanc
mitogenactiv
protein
kinaseextracellularregul
kinas
mapkerk
kinas
could
involv
process
anoth
possibl
basal
isg
signatur
induc
ifn
beta
rather
ifn
alpha
subtyp
reflect
defici
ifn
gamma
signal
observ
acut
vs
chronic
hcv
infect
regard
uniqu
ifn
beta
signal
axi
mediat
via
receptor
recent
identifi
sever
studi
demonstr
lambda
poorrespons
minor
allel
associ
high
basal
level
isg
provid
compel
evid
involv
genet
predisposit
also
mention
recent
discoveri
dinucleotid
polymorph
ttdg
upstream
lambda
gener
novel
ifn
lambda
variant
allel
dg
protein
may
reveal
altern
scenario
understand
function
architectur
type
iii
ifn
genom
region
influenc
outcom
hcv
infect
also
identifi
relationship
endogen
isg
upregul
poor
respons
ifn
alpha
treatment
ifn
lambda
creat
allel
dg
correl
unfavor
allel
tt
better
predictor
hcv
clearanc
role
tt
predict
respons
antihcv
therapi
without
ifn
report
review
see
interestingli
carrier
ifn
lambda
creat
dg
allel
found
significantli
higher
amount
isg
mrna
patient
homozyg
disrupt
tt
allel
moreov
relat
actual
ifn
lambda
transcript
carrier
dg
allel
isg
induct
hcv
infect
patient
measur
quantiti
ifn
lambda
mrna
present
significantli
stronger
isg
induct
without
observ
may
provid
possibl
explan
hcv
posit
patient
show
isg
stimul
liver
appar
absenc
induct
ifn
subtyp
hcv
therapi
evolv
rapidli
ifnbas
daaonli
regimen
relev
endogen
ifn
system
ifnfre
therapi
treatment
outcom
could
question
howev
recent
demonstr
hcv
clearanc
achiev
ifnfre
treatment
dda
regimen
accompani
hepat
downregul
type
ii
iii
ifn
receptor
isg
furthermor
abil
restor
intrahepat
type
ifn
signal
associ
prolong
hcv
suppress
altogeth
find
togeth
observ
rbv
shown
vitro
upregul
narrow
spectrum
isg
highlight
import
evalu
whether
variabl
express
compon
ifn
system
may
affect
clinic
outcom
ifnfre
regimen
hcv
patient
although
immunoregulatori
properti
type
ifn
appreci
sinc
ifn
still
administ
schedul
modal
reflect
antivir
antiprolif
activ
earli
studi
mous
tumor
model
demonstr
gener
longlast
antitumor
respons
type
ifn
depend
host
immun
mechan
part
reflect
identif
type
ifn
regul
class
histocompat
antigen
express
ifn
inde
import
regul
sever
compon
host
immun
activ
rang
stimul
lymphocyteand
monocytemedi
cytotox
activ
macrophag
natur
killer
nk
memori
cell
dendrit
cell
dc
ifn
alphabeta
fact
induc
dc
matur
upregul
costimulatori
activ
enhanc
capac
kill
tumor
cell
present
crosspres
antigen
ifn
alpha
also
play
key
role
polar
thelper
cell
toward
subtyp
enhanc
primari
antibodi
respons
solubl
antigen
deactiv
suppress
function
mice
human
regulatori
cell
treg
thu
enhanc
helper
cell
function
nk
cell
tumor
cytotox
immunomodulatori
activ
type
ifn
particular
effect
innat
immun
respons
immunolog
memori
account
efficaci
vaccin
adjuv
demonstr
influenza
infect
model
mice
well
melanoma
patient
recent
ifn
shown
pivot
role
render
immunogen
cell
death
induc
chemotherapi
thu
support
particip
immun
system
cytocid
activ
observ
correl
favor
respons
system
administr
ifn
alpha
appear
autoimmun
metastat
melanoma
patient
strongli
corrobor
hypothesi
induct
host
immunostimulatori
mechan
critic
factor
predict
antitumor
efficaci
ifn
nevertheless
larg
major
clinic
studi
effect
ifn
administr
immun
cell
monitor
therefor
import
part
mechan
action
disregard
allow
mechanisticbas
improv
therapeut
efficaci
ifn
receptor
repres
earli
element
innat
adapt
immun
evolut
physiolog
activ
consist
stimul
immun
defens
invas
foreign
patholog
element
potent
transient
action
quickli
extinguish
selfregulatori
mechan
discoveri
ifn
earli
studi
focus
two
multipl
properti
antivir
antiprolif
activ
identif
addit
member
ifn
famili
character
complex
properti
distinct
ifn
subtyp
increas
knowledg
regul
ifn
respons
progress
rapidli
realm
preclin
research
yet
incorpor
use
ifn
treatment
infecti
diseas
cancer
clinic
ifn
use
high
dose
intent
maintain
high
concentr
bodi
frequent
inject
sustain
releas
overal
therapeut
result
strategi
benefici
infecti
neoplast
diseas
diseas
especi
use
singl
agent
valu
ifn
therapi
limit
particularli
light
system
toxic
exampl
high
dose
ifn
effect
drastic
reduc
viremia
hcvinfect
patient
first
treatment
cycl
subsequ
viru
load
rise
ribavirin
requir
therapeut
efficaci
furthermor
benefici
effect
continu
exogen
ifn
ie
pegifn
hamper
induct
differ
mechan
refractori
receptor
internalizationdegrad
rapid
induct
soc
neg
regul
thu
limit
pegifn
activ
despit
persist
serum
nevertheless
pegifn
alpha
favor
pharmacokinet
pharmacodynam
improv
outcom
chc
patient
although
clear
activ
relat
acut
induct
isg
inde
sinc
approv
earli
chc
ifn
alpha
pegifn
alpha
use
hcv
patient
regardless
whether
preexist
type
ifn
signatur
could
make
patient
intrins
resist
ifn
therapi
may
reflect
activ
ifn
transduct
pathway
case
chronic
viral
infect
continu
ifn
administr
relationship
type
ifn
product
isg
express
host
genet
determin
viru
variabl
clearanc
hcv
understood
ifn
alphabas
therapi
likewis
properti
ifn
respons
may
also
import
new
era
daa
hcv
sinc
evid
indic
introduct
daa
ifn
regimen
may
affect
innat
immun
activ
thu
question
whether
ifn
alpha
andor
daa
use
effect
without
first
assess
endogen
type
ifn
activ
inde
ifn
known
antifibrot
action
proof
patient
advanc
stage
liver
diseas
clear
viral
infect
daa
complet
arrest
liver
diseas
progress
addit
antiangiogen
effect
high
dose
ifn
lead
reduct
tumor
vasculatur
antitumor
therapeut
effect
ifn
associ
immun
modul
brief
intens
product
type
ifn
plasmacytoid
dendrit
cell
stimul
innat
immun
similarli
induc
prolifer
memori
cell
activ
nk
cell
physiolog
immun
respons
type
ifn
play
crucial
brief
role
wherea
continu
ifn
product
lead
patholog
consequ
demonstr
system
lupu
erythematosu
consider
lead
reconsider
schedul
ifn
treatment
favor
administr
given
progress
delay
time
interv
avoid
refractori
mechan
induc
ifn
furthermor
ifn
therapi
direct
target
vascular
endothelium
monocytesdendrit
cell
lymphocyt
tumor
cell
etc
target
deliveri
strategi
requir
lower
dose
therefor
produc
less
system
side
effect
also
proapoptot
immunoadjuv
activ
ifn
combin
chemoor
radiotherapeut
treatment
increas
immunogen
die
tumor
cell
uptak
dendrit
cell
monitor
immun
cell
activ
consid
ifn
treat
patient
mechanisticbas
improv
therapeut
efficaci
base
observ
genet
variabl
ie
snp
lambda
ifn
lambda
chromosom
render
chc
patient
prone
viru
clearanc
ifn
treatment
ifn
treatment
person
consid
genet
variat
may
impact
treatment
viral
infect
cancer
similarli
monitor
known
mechan
resist
escap
use
virus
tumor
develop
drug
reduc
resist
could
improv
ifn
treatment
effect
observ
type
ifn
respons
deleteri
host
secondari
bacteri
fungal
infect
sever
autoimmun
diseas
certain
chronic
viral
infect
prompt
us
reflect
whether
ifn
alpha
optim
use
clinic
practic
instanc
detriment
effect
type
ifn
action
clearli
demonstr
lymphocyt
choriomening
viru
lcmv
pathogen
simian
immunodefici
viru
siv
hiv
infect
direct
causal
link
type
ifnisg
express
chronic
immun
activ
dysfunct
report
surpris
possibl
therapeut
target
either
type
ifn
product
emerg
new
therapeut
strategi
viral
diseas
howev
recent
demonstr
blockad
type
ifn
receptor
use
type
ifn
receptor
antagonist
siv
infect
rhesu
macaqu
diminish
antivir
gene
express
increas
siv
reservoir
size
acceler
tcell
deplet
progress
aid
despit
decreas
tcell
activ
thu
elev
type
ifn
signatur
deleteri
chronic
viral
infect
emphas
difficulti
associ
vivo
manipul
complex
biolog
system
observ
demonstr
consequ
manipul
ifn
signal
difficult
predict
vivo
therapeut
intervent
patient
conduct
caution
care
consider
physiolog
ifn
action
none
carolina
scagnolari
graduat
biolog
scienc
receiv
phd
microbiolog
virolog
post
graduat
school
degre
join
sapienza
univers
rome
assist
professor
virolog
current
chief
antivir
innat
immun
research
unit
depart
molecular
medicin
scagnolari
career
devot
viral
infecti
diseas
focus
princip
role
type
iii
interferon
control
acut
chronic
viral
infect
mostli
caus
respiratori
virus
hepat
c
viru
hiv
receiv
sivim
icarcroi
award
special
juri
price
sever
research
grant
sapienza
univers
institut
pasteur
intern
network
authorcoauthor
paper
appear
intern
journal
field
virolog
immunolog
federica
moschella
postdoctor
research
dr
enrico
proietti
appli
biotherapi
unit
dept
hematolog
oncolog
molecular
medicin
obtain
degre
biolog
scienc
phd
biochemistri
molecular
biolog
univers
napl
spent
year
postdoctor
research
fellow
columbia
presbyterian
hospit
new
york
research
mainli
focus
unravel
mechan
underli
antitumor
activ
combin
strategi
aim
enhanc
efficaci
immunotherapi
cancer
patient
particular
emphasi
type
interferonmedi
mechan
enrico
proietti
research
director
head
appli
biotherapi
unit
dept
hematolog
oncolog
molecular
medicin
istituto
superior
di
itali
obtain
md
board
certifi
clinic
immunolog
clinic
oncolog
visit
scientist
work
ion
gresser
laboratori
villejuif
franc
work
long
time
anticanc
immunomodul
activ
type
interferon
discov
immunoadjuv
properti
nowaday
research
group
focus
clinic
exploit
new
cancer
vaccin
modal
particular
interest
method
aim
reduc
cancer
immunesuppress
potenti
antitumor
immun
respons
